29 July 2026
NPRA warns of severe acute pancreatitis risk with GLP-1 and dual GLP-1/GIP receptor agonists. NPRA has received 504 reports of adverse events suspected to be linked with the diabetes/weight loss drugs, including two of pancreatitis and acute pancreatitis.
